Cantargia presents positive results for nadunolimab at AACR 2023 including new clinical data in pancreatic cancer ...Middle East

PR Newswire - News
LUND, Sweden, March 14, 2023 /PRNewswire/ -- Cantargia (Cantargia AB) (Nasdaq Stockholm: CANTA) today reported that two abstracts on its lead asset, the antibody nadunolimab (CAN04), have been selected for poster presentation at the AACR Annual Meeting 2023 (AACR 2023). A key finding is...

Hence then, the article about cantargia presents positive results for nadunolimab at aacr 2023 including new clinical data in pancreatic cancer was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Cantargia presents positive results for nadunolimab at AACR 2023 including new clinical data in pancreatic cancer )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News